Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

Documenti analoghi

• The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
  di: Chang, Shih-Chieh, et al.
  Pubblicazione: (2011)
• Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
  di: Zhang, Yan, et al.
  Pubblicazione: (2017)
• Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
  di: Banno, Eri, et al.
  Pubblicazione: (2016)
• Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
  di: Asami, Kazuhiro, et al.
  Pubblicazione: (2014)
• Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer: To Test or Not to Test?
  di: Gazdar, Adi F.
  Pubblicazione: (2011)